154 related articles for article (PubMed ID: 37692698)
1. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
[TBL] [Abstract][Full Text] [Related]
2. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
3. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
5. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
6. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
Gresham LM; Kirchhof MG
SAGE Open Med Case Rep; 2023; 11():2050313X231160926. PubMed ID: 36968984
[TBL] [Abstract][Full Text] [Related]
7. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
8. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
9. A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.
Wesolow JT; Jalali S; Clark LD
Cureus; 2021 Jul; 13(7):e16169. PubMed ID: 34367779
[TBL] [Abstract][Full Text] [Related]
10. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal.
Munera-Campos M; Plana-Pla A; Rivera N; Boada A; Ferrándiz C
Indian J Dermatol; 2020; 65(3):214-216. PubMed ID: 32565564
[TBL] [Abstract][Full Text] [Related]
12. A Case of Bullous Pemphigoid Associated With Nivolumab Therapy.
Gotera N; Weilg P; Heleno C; Ferrari-Gabilondo N
Cureus; 2022 May; 14(5):e24804. PubMed ID: 35686260
[TBL] [Abstract][Full Text] [Related]
13. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
14. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.
Shalata W; Weissmann S; Itzhaki Gabay S; Sheva K; Abu Saleh O; Jama AA; Yakobson A; Rouvinov K
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358869
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
18. Multiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy.
Olsen E; Svoboda SA; Montanez-Wiscovich M; Saikaly SK
J Immunother; 2024 Apr; 47(3):98-100. PubMed ID: 38009069
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
20. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
